Key Methodological Features of Randomized Controlled Trials of Alzheimer’s Disease Therapy

Publisher： Karger

E-ISSN： 1421-9824|10|6|534-540

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.10, Iss.6, 1999-11, pp. : 534-540

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metrifonate Therapy in Alzheimer’s Disease: A Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 4, 2000-06 ,pp. : 202-211

Karger

Access to resources Recommend Favorite

A Double-Blind Placebo-Controlled Randomized Trial of Melissa officinalis Oil and Donepezil for the Treatment of Agitation in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 31, Iss. 2, 2011-02 ,pp. : 158-164

Karger

Access to resources Recommend Favorite

Clinical Features of Rapidly Progressive Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 29, Iss. 4, 2010-05 ,pp. : 371-378

Karger

Access to resources Recommend Favorite

Donepezil Treatment of Patients with Severe Alzheimer’s Disease in a Japanese Population: Results from a 24-Week, Double-Blind, Placebo-Controlled, Randomized Trial

By  

Dementia and Geriatric Cognitive Disorders, Vol. 25, Iss. 5, 2008-04 ,pp. : 399-407

Karger

Access to resources Recommend Favorite

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite